MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer

Xiaoping Wu; Tianchi Liu; Ou Fang; Wenhua Dong; Fengjun Zhang; Lindsey Leach; Xiaohua Hu; Zewei Luo

doi:10.18632/oncotarget.6594

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer

Xiaoping Wu, Tianchi Liu, Ou Fang, Wenhua Dong, Fengjun Zhang, Lindsey Leach, Xiaohua Hu and Zewei Luo _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:2417-2432. https://doi.org/10.18632/oncotarget.6594

Metrics: PDF 2464 views | HTML 2991 views | ?

Abstract

Xiaoping Wu1, Tianchi Liu1, Ou Fang1, Wenhua Dong1, Fengjun Zhang1, Lindsey Leach2, Xiaohua Hu1, Zewei Luo1,2

1Laboratory of Population and Quantitative Genetics, Institute of Biostatistics, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China

2School of Biosciences, University of Birmingham, Birmingham, UK

Correspondence to:

Zewei Luo, e-mail: [email protected]

Xiaohua Hu, e-mail: [email protected]

Keywords: non-small cell lung cancer, therapeutic agent, MicroRNA-708-5p, metastasis, p21

Received: August 10, 2015 Accepted: November 21, 2015 Published: December 14, 2015

ABSTRACT

MicroRNAs (miRNAs) have recently been recognized as targets for anti-metastatic therapy against cancer malignancy. Development of effective miRNA mediated therapies remains a challenge to both basic research and clinical practice. Here we presented the evidence for a miR-708-5p mediated replacement therapy against metastatic lung cancer. Expression of miR-708-5p was substantially reduced in metastatic lung cancer samples and cancer cell lines when compared to non-metastatic counterparts. Expression of the miRNA suppressed cell survival and metastasis in vitro through its direct target p21, and inhibited the PI3K/AKT pathway and stem cell-like characteristics of lung cancer cells. Systemic administration of this miRNA in a mouse model of NSCLC using polyethylenimine (PEI)-mediated delivery of unmodified miRNA mimics induced tumor specific apoptosis. It also effectively protected the tested animals from developing metastatic malignancy without causing any observed toxicity. The findings strongly support miR-708-5p as a novel and effective therapeutic agent against metastatic malignancy of non-small cell lung cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6594

Publication Alerts

Research Papers:

MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer

Abstract